We are live on ! Find out more
TGI

TRV GP III Portfolio holdings

AUM $6.14M
1-Year Est. Return 45.44%
This Fund
S&P 500
This Quarter Est. Return
-42.25%
1 Year Est. Return
+45.44%
3 Year Est. Return
+169.98%
5 Year Est. Return
+802.39%
10 Year Est. Return
–
AUM
$176M
AUM Growth
-$58.7M
Cap. Flow
+$66M
Cap. Flow %
37.38%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
FULC icon
Fulcrum Therapeutics
FULC
+$66M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYGR icon
1
Voyager Therapeutics
VYGR
$189M
$110M 62.32%
6,391,176
– –
FULC icon
2
Fulcrum Therapeutics
FULC
$288M
$39.6M 22.43%
+5,962,202
New +$66M
NTGN
3
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
$16.8M 9.49%
9,741,636
– –
JNCE
4
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$10.2M 5.75%
3,048,780
– –

Similar funds

TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

TRV GP III's Q3 2019 Portfolio in Review

As of Q3 2019, TRV GP III held 4 positions worth $176M, down 25% from $235M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP III deployed $66M of net new capital in Q3 2019, opening 1 new position. Its largest new stake was Fulcrum Therapeutics: 5,962,202 shares worth $39.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP III's largest Q3 2019 buy was Fulcrum Therapeutics: 5,962,202 shares worth $39.6M.
  • TRV GP III's ten largest holdings make up 100% of its $176M portfolio in Q3 2019.
  • TRV GP III opened 1 new position and closed 0 in Q3 2019.
  • TRV GP III's portfolio value fell 25% quarter-over-quarter to $176M.

Based on TRV GP III's 13F filing for Q3 2019, filed 4 Nov 2019.